VPTDF - Ventripoint Attends 23rd Annual Canadian Echo Weekend and Grants Stock Options
(TheNewswire)
Toronto, Ontario – TheNewswire –April 20, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) attended the 23 rd AnnualCanadian Echo Weekend – 2021 Digital Edition, which was organized bythe Canadian Society of Echocardiography (CSE).
Ventripoint participated as a sponsor for this year’sconference and received a high profile. The Company had a prominentbooth in the virtual exhibit hall and showcased a demo video, VMS+3.0clinical materials, a signup sheet for potential researchcollaborators, and an advertisement for the next webinar to be held inMay.
Outcomes from the weekend were:
-
1. A new application wasidentified, and a potential lead investigator was engaged,
-
2. Cardiologists signed up for theforthcoming webinar entitled “Remembering the forgotten ventricle– exploring the benefits of accurate and reliablemeasurements”,
-
3. The Company was able to advancediscussions with key cardiologists to conduct clinical evaluations,where the VMS can uniquely provide better and more timely information. These studies will be initiated once echocardiography services canfully re-open and resume normal operations.
The CSE is a non-profit organization comprised of 2,000cardiovascular professions and strives to promote high qualityechocardiographic services across Canada. This year’s virtualconference had an attendance of over 1,100 delegates that includedcardiologists, internists, sonographers, and trainees from across thecountry and outside Canada.
In other news, on April 12, 2021 the Company granted100,000 stock option grants to a consultant and 100,000 option grantsto an employee. The stock option grants vested immediately and havean exercise price of $.50. After this grant, the Company has 836,250options remaining for future grants.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.